Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
Celularity Inc. filed a Current Report on Form 8-K regarding its annual meeting of stockholders held on July 13, 2022. The filing was signed on July 14, 2022. The company is incorporated in Delaware and its Class A common stock and warrants trade on Nasdaq under the symbols CELU and CELUW.
Meeting Results and Key Corporate Actions
- Stockholders elected Peter Diamandis, M.D., Diane Parks, and Andrew C. von Eschenbach, M.D. as Class I directors to serve until the 2025 annual meeting or until their successors are duly elected and qualified.
- Peter Diamandis, M.D.: 90,263,297 votes for, 191,273 votes withheld, and 3,325,427 broker non-votes.
- Diane Parks: 90,395,742 votes for, 58,828 votes withheld, and 3,325,427 broker non-votes.
- Andrew C. von Eschenbach, M.D.: 90,243,694 votes for, 210,876 votes withheld, and 3,325,427 broker non-votes.
- Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- The auditor appointment received 93,609,560 votes for, 24,502 votes against, 145,935 abstentions, and no broker non-votes.
Financial Metrics and Material Changes
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics. It also does not report material changes versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide financial guidance, operating outlook, management commentary, or specific risks and contingencies. The primary corporate actions were the election of three directors and ratification of the independent auditor.
Investor Verification Points
- Verify the certified vote totals and the three-year terms of the elected Class I directors.
- Confirm Deloitte & Touche LLP’s appointment for the fiscal year ending December 31, 2022.
- Review the company’s other SEC filings for financial performance, liquidity, financing needs, and business or clinical-development risks, none of which are addressed in this 8-K.